COVID-19

Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company…

9 months ago

MediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress

YAVNE, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation enzymatic…

9 months ago

Moderna Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation

CAMBRIDGE, MA / ACCESSWIRE / September 8, 2023 / Moderna, Inc. (Nasdaq:MRNA) has been notified that TRC Capital Investment Corporation…

9 months ago

Rhythm Pharmaceuticals Announces Update to September Conference Participation

BOSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the…

9 months ago

Advanced Health Intelligence Ltd Signs Collaboration Agreement with Bin Farhood International Business Management Group L.L.C

Highlights AHI enters collaboration with His Excellency Dr Obaid Alketbi.Bin Farhood Group Founders have worked with and within the Government…

9 months ago

Hyperfine, Inc. to Present at Gilmartin Group Emerging Growth Showcase

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared…

10 months ago

Theralase(R) Closes Private Placement Equity Financing

TORONTO, ON / ACCESSWIRE / September 7, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), is a clinical…

10 months ago

New FAIR Health Study Examines Use of Telehealth in Connecticut from 2020 to 2022

Over 90 Percent of Connecticut Patients Used Telehealth to See Healthcare Providers Whom They Also Saw in Person NEW YORK,…

10 months ago

Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013

Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport…

10 months ago